Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copay Coupons May Skew Medicare Part B Reimbursement, GAO Says

Executive Summary

Manufacturer-generated average sales price reports used by CMS to set Part B drug reimbursement doesn’t reflect net price after coupons.

You may also be interested in...



Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need

New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need. 

Part B Demo Comments Overwhelmingly Negative, Uniform In Content

More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.

Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

Centers for Medicare and Medicaid Services’ standard for determining whether drugs produce a clinically meaningful improvement in cognition that would allow for broader Medicare coverage is unclear. But Eisai/Biogen’s lecanemab is likely to serve as a first test.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS119048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel